Craft

Eidos Therapeutics

Stock Price

$122.2

2021-01-28

Market Capitalization

$4.8 B

2021-01-28

Revenue

$26.7 M

FY, 2019

Eidos Therapeutics Summary

Company Summary

Overview
Eidos Therapeutics is a biotech company developing novel, genetically targeted therapies to improve the lives of patients. The Company's approach combines a traditional focus on drug development with a unique corporate model, allowing rapid translation of early stage science into medicines that treat disease at its source.
Type
Public
Status
Active
Founded
2013
HQ
San Francisco, CA, US | view all locations
Website
https://eidostx.com
Cybersecurity rating
Sectors

Key People

  • Neil Kumar, Chief Executive Officer

    • Jonathan Fox

      Jonathan Fox, President and Chief Medical Officer

    • Uma Sinha, Chief Scientific Officer, Director

    • Matt Outten, Chief Commercial Officer

      LocationsView all

      2 locations detected

      • San Francisco, CA HQ

        United States

        1800 Owens St, San Francisco

      • San Francisco, CA

        United States

        101 Montgomery St #2550, San Francisco

      Eidos Therapeutics Financials

      Summary Financials

      Revenue (Q3, 2020)
      $127.0K
      Net income (Q3, 2020)
      ($30.2M)
      Cash (Q3, 2020)
      $147.3M
      EBIT (Q3, 2020)
      ($29.4M)
      Enterprise value
      $7.6B

      Footer menu